

Article 34

Claims

1. A method of preventing or controlling cataract or cataract-like disorders in the eye of a mammalian subject which comprises administering to the subject an effective amount of one or more inhibitors of TGF β .
2. A method according to claim 1 wherein the one or more inhibitors of TGF β are selected from proteins, glycoproteins and proteoglycans.
3. A method according to claim 2 wherein the protein inhibitors of TGF β are selected from antibodies and peptide growth factors.
4. A method according to claim 2 wherein the glycoprotein inhibitors of TGF β are selected from α_2 -macroglobulin, laminin and collagen.
5. A method according to claim 2 wherein the proteoglycan inhibitors of TGF β are selected from decorin, heparan sulfate proteoglycans and biglycan.
6. An ophthalmological formulation comprising one or more inhibitors of TGF β in an ophthalmologically acceptable carrier but excluding conventional pharmaceutically acceptable carriers.
7. An ophthalmological formulation according to claim 6 wherein the inhibitors of TGF β are as defined in claim 2, 3, 4 or 5.
8. A method of preventing or controlling "aftercataract" formation in the eye of a mammalian subject following lens implant surgery which comprises implanting in the eye of the subject a lens coated with one or more TGF β inhibitors.
9. A method according to claim 8 wherein the TGF β inhibitors are as defined in claim 2, 3, 4 or 5.
10. A lens implant coated with one or more TGF β inhibitors.
11. A lens implant according to claim 10 coated with one or more TGF β inhibitors as defined in claim 2, 3, 4 or 5.
12. The use of inhibitors of TGF β in the manufacture of an ophthalmological formulation for preventing or controlling cataract or cataract-like disorders.

06648092-062196
96T290-26034980

- 25 -

13. Use according to claim 12 wherein the TGF β inhibitors are as defined in claim 2, 3, 4 or 5.

add
A1

add
B1

add
C1

09643092 062196